Somewhat Positive Press Coverage Somewhat Unlikely to Affect Imprimis Pharmaceuticals (IMMY) Stock Price

News stories about Imprimis Pharmaceuticals (NASDAQ:IMMY) have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Imprimis Pharmaceuticals earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 45.2660281876376 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Imprimis Pharmaceuticals (NASDAQ IMMY) remained flat at $$1.72 during midday trading on Thursday. 80,747 shares of the stock traded hands, compared to its average volume of 155,200. Imprimis Pharmaceuticals has a 12 month low of $1.35 and a 12 month high of $4.69. The firm has a market cap of $35.32, a price-to-earnings ratio of -1.86 and a beta of -0.40. The company has a quick ratio of 1.28, a current ratio of 1.67 and a debt-to-equity ratio of 3.94.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Imprimis Pharmaceuticals (IMMY) Stock Price” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3125760/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-imprimis-pharmaceuticals-immy-stock-price.html.

Imprimis Pharmaceuticals Company Profile

Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.

Insider Buying and Selling by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.